Navigation Links
Xanodyne Announces Planned President & CEO Succession
Date:5/27/2010

NEWPORT, Ky., May 27 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Natasha Giordano has been named to the position of President and Chief Executive Officer and will be elected to the Company's Board of Directors, succeeding Michael J. Valentino.

The management transition was planned by the Board and follows a year of significant new product and commercial successes under Mr. Valentino's leadership.  In 2009, Xanodyne received FDA approval for Zipsor®, a new treatment option indicated for relief of mild to moderate acute pain in adults.  The Company also received FDA approval for Lysteda™ indicated for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.  Recently, Xanodyne announced that is has tightly focused the strategic direction for the company on the pain management market, and the related sale of Lysteda™ to Ferring Pharmaceuticals.  Xanodyne has a strategic partnership with Ferring for the co-promotion of Zipsor®.

Ms. Giordano most recently served as the company's Chief Operating Officer during this period of unprecedented success.  Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and prior to Xanodyne served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry.  Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. Giordano said, "I look forward to working with the Board and management team in continuing to drive toward our vision of being a leader in the pain management category.  We have a proven track record of bringing innovative products to the market, and developing strategic partnerships where desired,  as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."

Mr. Valentino said, "I am very pleased to be leaving Xanodyne with high caliber talent on the management team, and throughout the organization.  Natasha's knowledge of the industry and her continued strong leadership will sustain the momentum as Xanodyne focuses its growth in pain management. The successful launch of Zipsor®, the portfolio of legacy brands, and strategic divestiture of non-core assets, including Lysteda™, position Xanodyne well for the future."

Rolf Classon, Chairman of the Board said, "We are very pleased with this planned leadership succession.  Mike expanded his Board responsibility to include the CEO role last year with the intent of seeing our drugs through approval and commercialization, and building a team to refine the strategic direction of the business.  The successful partnership between Mike and Natasha allows us a smooth senior management transition as we move forward and execute against our strategic priorities. On behalf of myself and the Board, I'd like to thank Mike for his contributions to the Board and for his stewardship of the Company during this crucial year. "

About Xanodyne Pharmaceuticals, Inc.

Xanodyne, which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused exclusively on pain management. Xanodyne markets a portfolio of products consisting of prescription pain management pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing its pipeline of product candidates targeted at significant potential segments of the pain management market including chronic and severe pain. For more information visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
2. Xanodyne Announces Renewed Focus on Pain Management Market
3. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
4. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
5. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
6. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. FDA Announces Collaboration With Drugs.com
11. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):